Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.
KALAMAZOO, Mich. — Those who are recovering from addiction now have a new lifeline in Kalamazoo. Reach Sober Living has just ...
Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback